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ABSTRACT: 
Objective: The clinical benefit of tricuspid annuloplasty (TA) in patients undergoing mitral 
valve surgery (MVS) is still debated. We evaluated the immediate surgical success, post-
operative outcome and the medium-term effect of TA in MVS. 
Methods: Patients were included between 09-2003 and 12-2009 and followed until 09-2013 
to achieve a median follow-up time of 5 years (IQ3.7-6.9). The endpoint of mortality due to 
cardiac causes and combined endpoint of cardiac mortality or hospitalization for heart failure 
were evaluated. Propensity score adjusted cox regression was used to evaluate the clinical 
benefit of TA at the time of MVS. 
Results: Of 150 patients (84 female;67±12 years), 82 presented with tricuspid regurgitation 
(TR)<2/4 and underwent isolated MVS. Sixty-eight patients presenting with TR≥2/4, 31 
underwent isolated MVS whereas 37 underwent additional TA.  
In patients with preoperative TR≥2/4, TR was significantly reduced until 5 years post-
operatively [mean reduction 0.81±1.31;p=0.04] when additional TA was done. The combined 
endpoint occurred in 29% vs. 6% at 1 year and in 57% vs. 39% at 5 years follow-up for 
patients with isolated MVS and patients undergoing concomitant TA, respectively. 
Patients with preoperative TR≥2/4 had worse unadjusted survival  than those with TR<2/4 
(log-rank p=0.009) In the patients with TR≥2/4, propensity score-adjusted risk for the  
combined end-point was higher in those with isolated MVS versus MVS with additional TA 
[Cox HR 2.855(1.082-7.532);p=0.035].  
Conclusion: Additional TA is an effective surgical measure to reduce functional TR severity. 
This approach results in a decreased risk of cardiac mortality and hospitalization in patients 
with preoperative TR≥2/4.   
 
Key Words: Mitral regurgitation, Tricuspid valve disease, Valve disease surgery. 
	 4	
KEY QUESTIONS: 
What is already known about this subject? 
Tricuspid valve regurgitation often accompanies mitral valve regurgitation. Development or 
deterioration of tricuspid valve function is known to be associated with decreased functional 
capacity and increased mortality. Although no outcome study has proven the clinical benefit 
of tricuspid valve annuloplasty at the time of mitral valve surgery, a liberal approach towards 
tricuspid annuloplasty is advised in the guidelines. 
 
What does this study add? 
Because clinical and echocardiographic factors influence both the decision to perform 
tricuspid annuloplasty as well as outcome, we adjusted for these factors via propensity scores 
in our regression models. After adjustment, patients with preoperative tricuspid regurgitation 
undergoing isolated mitral valve surgery had worse outcome for the combined endpoint of 
cardiac mortality or hospitalization for heart failure. This endpoint was mainly driven by an 
increased incidence of heart failure. 
 
How might this impact on clinical practice? 
This study provides evidence for the clinical benefit of performing concomitant tricuspid 
annuloplasty. It supports a more liberal approach towards tricuspid annuloplasty at the time 
of left-sided cardiac surgery both in functional and degenerative mitral regurgitation. 
However, due to the observational nature of the data and the relatively small sample size, 
further research should be done to confirm the existence and the causality of the association 
between outcomes and surgical practices.   
	 5	
INTRODUCTION: 
Functional tricuspid regurgitation (TR) often accompanies mitral regurgitation (MR). 
Although TR may be only mild at the time of surgery, TR severity progresses after isolated 
mitral valve surgery in about 30% of patients and can occur years after the initial left-sided 
surgery.[1, 2, 3] The complex pathophysiology of functional TR makes the natural history 
unpredictable.[4, 5] Increasing TR severity is known to be associated with worse 
prognosis.[1, 6] Furthermore, reoperation for isolated TR is associated with a high 
perioperative, short- and long-term mortality whereas performing tricuspid annuloplasty at 
the time of mitral valve surgery adds little time to the procedure.[7, 8] Therefore, a more 
liberal approach in performing tricuspid valve repair at the time of MV surgery is now 
advocated by both the ESC and the AHA/ACC guidelines on valvular heart disease.[9, 10] 
Although such an approach results in favourable remodelling of the right ventricle and lower 
recurrence of TR, data on clinical outcome are scarce. [3, 11, 12] Improved mid-term 
survival of concomitant tricuspid annuloplasty has been reported in patients with functional 
MR due to, mainly ischemic, cardiomyopathy.[13] However, the gross majority of mitral 
valve surgery is performed for chronic degenerative valvular disease.[14] Especially in this 
patient population, concomitant tricuspid annuloplasty is controversial.[15] Comparison of 
the outcome in patients undergoing mitral valve surgery with or without tricuspid 
annuloplasty is notoriously difficult because the former often present in a worse clinical state 
with more severe TR, higher NYHA functional class and decreased right ventricular 
function.[3] Cross-sectional studies therefore failed to show improved outcome for patients 
undergoing simultaneous tricuspid annuloplasty and mitral valve surgery in the past. [16, 17]  
The aim of our study was to assess the surgical success of mitral valve surgery with or 
without tricuspid annuloplasty, to examine post-operative outcome and to evaluate the 
	 6	
clinical benefit of tricuspid annuloplasty in the setting of mitral valve surgery corrected for 
pre-operative parameters using a propensity score analysis. 
 
METHODS: 
Patient selection and data collection: 
From the institutional database of Cardiac Surgery at the University Hospitals Leuven, 
patients undergoing mitral valve surgery were retrospectively included from September 2003 
until December 2009 and followed until September 2013. All patients had their follow-up at 
the University Hospitals Leuven, a tertiary care center. Patients with primary tricuspid valve 
pathology, redo surgery or severe non-cardiac disease at the moment of inclusion were 
excluded.  
Patients underwent either isolated mitral valve surgery or mitral valve surgery in combination 
with tricuspid annuloplasty. Patients were divided into 3 groups: (1) patients with TR<2/4 
undergoing isolated mitral valve surgery (Group TR-/MVS); (2) patients with TR≥2/4 
undergoing isolated mitral valve surgery (Group TR+/MVS) and (3) patients with TR≥2/4 
undergoing mitral valve surgery in combination with tricuspid annuloplasty (Group 
TR+/MVS+TA). 
The mitral valve was repaired whenever feasible, otherwise, mitral valve replacement was 
performed. The decision to perform concomitant tricuspid annuloplasty was taken after 
multi-disciplinary discussion by the institutions heart team. Demographic and clinical data as 
well as echocardiographic data were included. Post-operative data including 
echocardiography immediately post-operative, at 6-month, 3 years and 5 years follow-up 
were reviewed.  Outcome for every patient was evaluated. The local ethics committee 
approved patient inclusion and analysis.  
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Transthoracic echocardiography: 
Left ventricular end-diastolic diameter was obtained from a parasternal long axis view. Left 
ventricular ejection fraction was obtained by the biplane method of disks (modified 
Simpson’s rule). Right ventricular diameter was obtained at end-diastole and at the mid-
ventricular level from a right ventricle focused apical 4-chamber view. Tricuspid annular 
diameter was obtained at end-diastole from the apical 4-chamber view. Tricuspid annulus 
systolic excursion (TAPSE) was obtained from an apical 4-chamber view by placing the M-
mode cursor through the anterior tricuspid annulus. Valvular regurgitation was assessed 
semi-quantitatively by colour Doppler echocardiography and graded from 0-4/4. The right 
ventricle to right atrial pressure gradient was calculated from the tricuspid regurgitant 
velocity by means of the simplified Bernoulli equation.  
 
Endpoints: 
Cardiac mortality and the combined endpoint of cardiac mortality or hospitalization for heart 
failure were evaluated for each group. Cardiac mortality was defined as death due to end-
stage heart failure, cardiogenic shock and sudden cardiac death. Heart failure was diagnosed 
when the patient presented with both clinical signs (NYHA functional class III and higher or 
signs of sodium and water retention) and evidence of fluid overload on echocardiography or 
an elevated NT-proBNP was observed at presentation.  
 
Statistical analysis: 
Continuous data and categorical data are represented by means and standard deviation or 
frequencies and percentages, respectively.  
First, pre-operative demographic data and echocardiographic data were analysed. Data from 
patients with significant TR≤2/4 undergoing either isolated mitral valve surgery or 
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concomitant tricuspid annuloplasty were compared by unpaired t-test or Fisher’s exact test 
where applicable.  
Next, surgical success was evaluated by comparison of pre-operative echocardiographic data 
with echocardiography directly post-operative, at 6 months, 3 years and 5 years post-
operatively by the paired t-test. Differences between patients with TR≥2/4 undergoing mitral 
valve surgery with or without tricuspid annuloplasty were assessed by the unpaired t-test. 
Third, the occurrence of cardiac mortality and the combined endpoint of cardiac mortality or 
hospitalization for heart failure were evaluated for each group by Kaplan-Meier survival 
analysis.  
Last, a non-parsimonious propensity score was constructed by multivariate binary logistic 
regression and the probability was calculated for each patient with TR ≥ 2/4 to be allocated 
by the heart team to concomitant tricuspid annuloplasty (Group TR+/MVS vs. Group 
TR+/MVS+TA). Based on current guidelines and practice in our hospital, age, preoperative 
NYHA functional class, TR severity, tricuspid annular diameter and preoperative tricuspid 
annular plane systolic excursion (TAPSE) were included in the model [C-statistic 0.861 
(95%CI=0.767-0.956); Hosmer Lemeshow p=0.279]. 
Multivariate Cox regression was performed with the propensity score and the surgical 
approach as variables, and propensity score-adjusted survival curves were plotted 
subsequently.  
All tests were two-tailed. A P-value <0.05 was considered significant. Analyses were 
performed using SPSS® (version 22 SPSS, Chicago, USA). 
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RESULTS: 
Patient inclusion: 
From September 2003 until December 2009, 882 patients underwent mitral valve surgery at 
the University Hospitals Leuven. Of these, 625 were referred from and later followed outside 
the hospital. From the remaining 257 patients, 17 were lost to follow-up. Another 90 patients 
were excluded for various reasons as is summarized in Figure 1. The study cohort comprised 
the remaining 150 patients. Median follow-up time was 5 years (IQ range 3.7-6.9). 
 
Patient characteristics: 
Demographic, echocardiographic, and post-operative data are listed in Table 1. Eighty-two 
patients had pre-operative TR<2/4 (group TR-/MVS). From the 68 patients with TR ≥ 2/4, 37 
underwent concomitant tricuspid valve repair (group TR+/MVS+TA), and 31 patients 
underwent isolated mitral valve surgery (group TR+/MVS). Patients in group TR+/MVS+TA 
had significantly more TR and significantly lower TAPSE than patients in group TR+/MVS.  
The etiology of mitral valve regurgitation can be found in Table 1. 
In 82 (55%) patients, mitral valve repair was feasible. The other 68 (45%) patients underwent 
mitral valve replacement, in 37 (54%) cases with a mechanical prosthetic valve. The 
distribution of the surgical strategy was not significantly different across groups (Fisher’s 
Exact p=0.518). 
Of 37 patients undergoing additional tricuspid annuloplasty, 21 (56%) underwent De Vega 
annuloplasty and 16 (44%) underwent ring annuloplasty.  
 
Surgical success after mitral and tricuspid valve surgery: 
Significant reduction of MR was observed in all patients early post-operatively and at 6 
months follow-up. Results are summarized in Table 2. In patients presenting without 
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significant TR (Group TR-/MVS), TR post-operatively was slightly but significantly 
increased (p<0.001 immediately post-operatively, p=0.018 at 6 months, p<0.0001 at 3 years 
follow-up and p<0.0001 at 5 years follow-up), albeit still in what is considered to be the 
physiological range. In Group TR+/MVS, no significant decrease of TR could be seen in 
follow-up. Patients undergoing simultaneous tricuspid and mitral valve surgery (Group 
TR+/MVS+TA) presented with a large and significant decrease of TR post-operatively. Mean 
reduction in TR severity was 1.5 ± 1.1 immediately post-operatively (p<0.001), 1.13 ± 1.2 at 
6 months (p<0.001), 0.89 ± 1.2 at 3 years (p<0.001), and 0.81 ± 1.3 at 5 years follow-up 
(p=0.040).  
A trend towards lower TR severity in patients with preoperative TR undergoing tricuspid 
annuloplasty (TR+/MVS+TA) compared to patients undergoing isolated mitral valve surgery 
(TR+/MVS) throughout follow-up. (Table 2) 
TR severity was similar pre-operatively for patients undergoing De Vega annuloplasty 
compared to patients undergoing ring annuloplasty (2.7±0.7 vs. 2.6±1.0; p=0.574). De Vega 
annuloplasty resulted in significant reduction of TR post-operatively (1.2±0.7; p<0.0001), at 
6 months (1.8±0.9; p=0.005) and at 3years follow-up (2.0±0.67; p=0.006). Ring annuloplasty 
equally resulted in significant reduction of TR severity post-operatively (1.1±0.8; p= 
p<0.0001), at 6 months (1.1±0.8; p<0.0001) and at 3 years follow-up (1.3±0.7; p=0.018). 
Ring annuloplasty resulted in a more pronounced reduction of TR severity at 6 months 
(1.8±0.9 vs. 1.1±0.8; p=0.015) and at 3 years follow-up (2.0±0.7 vs. 1.3±0.7; p=0.023).  
NYHA functional class was significantly better compared to pre-operatively in all patients, 
alive at 6 months follow-up. 
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Short- and medium-term clinical outcome after mitral and tricuspid valve surgery: 
Early post-operative all-cause mortality at 30 days and 3 months was 3.3% and 6% 
respectively.(Table 1) Event-rate for the combined endpoint of cardiac mortality or 
hospitalization for heart failure, for cardiac mortality and for hospitalization for heart failure 
can be found in Table 3. 
Event free survival was significantly better in patients presenting without significant 
preoperative TR (<2/4), compared to patients with preoperative TR > 2 (30-day cardiac 
mortality=2.4% vs 4.4%; 1-year=3.7% vs 10.6%; 5-year=7% vs 22.3%; Log Rank p=0.009). 
In unadjusted analysis, there was no difference in cardiac mortality between patients with 
TR≥2/4 undergoing isolated mitral valve surgery (Group TR+/MVS) and patients undergoing 
additional tricuspid annuloplasty (Group TR+/MVS+TA) (30-day cardiac mortality=9.7% vs 
0%; 1-year=16.1% vs 5.6%; 5-year=24.6% vs 20.3%; Log Rank p=0.414) whereas a trend 
towards better outcome for the combined endpoint of cardiac mortality or hospitalization for 
heart failure in the TR+/MVS+TA group could be seen (30 day event-rate = 9.7% vs 0%; 1-
year = 29% vs 5.6%; 5-year=57.2% vs 39.4%; Log Rank p=0.077).(Figure 2 and Table 3)  
 
When incorporating the propensity score into a multivariable Cox regression model, no 
significant benefit in cardiac mortality of additional tricuspid annuloplasty in patients with 
preoperative TR≥2/4 could be observed [HR 2.9 (0.8-10.7); p=0.108], whereas propensity 
score-adjusted event-free survival for the combined endpoint of cardiac death or 
hospitalization for heart failure was significantly better for patients with preoperative TR >2 
undergoing additional tricuspid annuloplasty [HR 2.9 (1.1-7.5); p=0.034]. (Figure 3) 
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DISCUSSION: 
This study shows that additional tricuspid annuloplasty at the time of mitral valve surgery 
significantly reduces TR severity postoperatively. Patients with TR ≥ 2/4 who undergo 
simultaneous mitral valve surgery and tricuspid annuloplasty have an improved event-free 
survival for the combined endpoint of cardiac mortality or hospitalization for heart failure.  
 
The value of tricuspid annuloplasty with mitral valve surgery is still debated. Both the 
European and American guidelines on valvular heart disease have implemented indications 
for concomitant tricuspid annuloplasty at the time of mitral valve surgery in their 
recommendations.[9, 10] Even more so, some authors advocate tricuspid annuloplasty in the 
absence of preoperative TR to prevent progression of TR in the long term.[18, 19] On the 
other hand, others question the value of concomitant tricuspid annuloplasty especially in 
degenerative mitral regurgitation. [15].  
 
Increased pulmonary arterial pressure, right ventricular and tricuspid valve annular 
dimensions contribute independently to functional TR.[20, 21, 22] Although surgery of the 
mitral valve can reduce the increased pulmonary arterial pressure caused by chronic MR, 
structural alterations at the level of the right ventricle often persist after isolated mitral valve 
surgery.[23, 24] Because of this, it is clear that TR doesn’t resolve after isolated mitral valve 
surgery and even progresses after successful left-side valve surgery.[1] Progression or 
persistence of TR in the setting of mitral valve surgery occurs frequently and is associated 
with worse prognosis.[1, 2, 3] If we aim to reduce TR or prevent the development of TR, 
tricuspid annuloplasty should be considered at the time of mitral valve surgery. The 
durability of tricuspid annuloplasty in the setting of mitral valve disease has been shown in 
other published series.[25] Our data show successful reduction of MR severity and NYHA 
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functional class in all surgical-treated patients. However, when preoperative TR was present, 
there was no significant reduction of TR when the tricuspid valve was left untreated. On the 
other hand, persistent reduction of TR up to 5 years post-operatively was noted in the patient 
group undergoing tricuspid annuloplasty. Both De Vega annuloplasty and Ring annuloplasty 
resulted in significant reduction of TR severity. However, as shown before, this reduction 
was more pronounced when ring annuloplasty was performed.[26]  
 
Although tricuspid annuloplasty successfully reduces TR, the net clinical benefit of 
performing simultaneous tricuspid valve surgery is unclear.[25] In patients with functional 
MR, mainly due to ischemic cardiomyopathy, 5-year mortality was lower in patients 
undergoing tricuspid annuloplasty at the time of mitral valve repair.[13] These data were 
adjusted for left ventricular parameters, as possible confounders of outcome. Opposed to this, 
several studies failed to show that tricuspid annuloplasty is beneficial in patients with other 
causes of MR.[16, 17] Especially in degenerative mitral valve disease, the value of tricuspid 
annuloplasty is controversial. Yilmaz et al. have reported a low need for tricuspid valve 
reoperation after isolated mitral valve surgery for mitral valve prolapse.[15] A possible 
explanation might be that recommendations for degenerative mitral valve disease are more 
clearly defined, and surgery is often offered earlier in the disease process compared to 
functional mitral regurgitation. However, even in this patient cohort, TR was ≥ 3/4 in 23% of 
patients at 3-5 years follow-up, regardless of preoperative TR severity. The clinical 
importance of this is uncertain, and the value of tricuspid annuloplasty to reduce TR in these 
patients remains to be proven.  
 
In addition, a registry including post-operative results in 17 centers showed a higher mortality 
and an increased operative time in patients undergoing additional tricuspid annuloplasty.[27] 
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In our patient cohort, we observed a higher, although not significant, incidence of permanent 
pacemaker implantation in the TR+/MVS+TA group compared to the TR+/MVS group 
(27.8% vs 10%; p=0.153). On the other hand, additional tricuspid annuloplasty was not 
associated with higher post-operative mortality in our study sample and no increased 
mortality was reported in studies from centers where a liberal approach towards tricuspid 
annular repair is practiced.[3, 7, 8] 
 
A comparison of both surgical approaches is hampered by the heterogeneity of patients. The 
decision to operate on the tricuspid valve concomitantly with the mitral valve is taken by 
multi-disciplinary consultation by the institution’s heart team. This often results in proposing 
the combined approach in “sicker” patients with already decreased right ventricular function, 
more dilated tricuspid valve annulus, more severe TR and in higher NYHA functional class. 
These are all known determinants of worse post-operative outcome. [3, 7, 8] To adjust for 
possible confounders, we calculated the probability for allocation to one of the surgical 
strategies for each patient. After adjustment, an improved event-free survival for the 
combined end-point of cardiac mortality or hospitalization for heart failure could be shown in 
patients with preoperative TR undergoing mitral valve surgery with tricuspid annuloplasty 
(Group TR+/MVS+TA).(Figure 3) The better event-free survival for patients undergoing 
simultaneous tricuspid annuloplasty is mainly due to a lower number of hospitalizations for 
heart failure.(Table 3) The volume-load associated with TR increases stroke work of the right 
ventricle and impairs ventricular interdependence.[28, 29] Theoretically, tricuspid 
annuloplasty should better preserve right ventricular function post-operatively and in the 
long-term. However, the relation between right heart failure and TR severity is still 
incompletely understood. Some suggest that TR is caused by right ventricular failure rather 
than vice-versa.[30] Indeed, we observed higher TR severity and lower right ventricular 
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function in patients undergoing additional tricuspid annuloplasty. This would mean that 
repairing tricuspid competence does not restore ventricular function. However, others have 
shown favourable remodelling of the right ventricle after tricuspid annuloplasty, especially in 
patients with severe TR preoperatively.[11, 12] In our patient cohort, with a mixed etiology 
of mitral regurgitation, we now add to this evidence with an improved event-free survival.  
 
Lastly, 32% of patients undergoing concomitant tricuspid annuloplasty had a tricuspid 
annulus diameter >40 mm or >21 mm/m2 as assessed by echocardiography. The better 
survival observed in the tricuspid annuloplasty group could be an indication for an even more 
liberal approach towards tricuspid annuloplasty. It seems to us, that current cut-off values for 
tricuspid annular dimensions are quite conservative and it seems obligatory to integrate 
several parameters in the decision process in this difficult patient population. Conversely, 
29% of patients with TR≥2/4 preoperatively undergoing isolated mitral valve surgery would 
currently have a IIa indication for tricuspid annuloplasty according to current guidelines. The 
exact indication for performing simultaneous tricuspid annuloplasty remains difficult to 
determine, exactly because of this multi-causality. However, the heart team should be alerted 
for TR progression during follow-up and if any doubt about the necessity, performing 
tricuspid annuloplasty seems to be the wiser decision. 
 
CONCLUSION: 
These data provide evidence on the clinical benefit to perform tricuspid annuloplasty in 
conjunction with mitral valve surgery in patients with TR≥2/4. Tricuspid annuloplasty is an 
effective and durable surgical technique that results in a decreased risk for mortality and 
hospitalization for heart failure. 
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LIMITATIONS: 
Our results are based on a retrospective analysis of a relatively small cohort of patients 
followed in a single institution. However, this resulted in accurate data of the studied patients 
and propensity score adjustment tried to eliminate surgical selection bias, though residual 
confounding may persist.  
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TABLES: 
Table 1: Demographic, pre-operative echocardiographic parameters and post-operative 
variables in patients without significant TR (Group TR-/MVS; n=82) and patients with 
significant TR undergoing either isolated mitral valve surgery (Group TR+/MVS; n=31) 
or combined tricuspid and mitral valve surgery (Group TR+/MVS+TA; n=37).  
 Group 1 Group 2 Group 3  
  TR-/MVS TR+/MVS TR+/MVS+TA P Group 2 vs 3 
Demographics     
Female gender 42 (51%) 17 (55%) 27 (73%) §0.135 
Age (years) 64 (12) 72 (8) 70 (11) 0.383 
BMI (kg/m2) 26.8 (5.4) 26.1 (3.8) 24.7 (4.2) 0.146 
Creatinine (mg/dL) 1.22 (1.15) 1.22 (0.42) 1.18 (0.32) 0.634 
NYHA functional class 2.2 (0.9) 2.5 (0.8) 2.6 (0.7) 0.741 
Atrial fibrillation 30 (36.6%) 18 (58.1%) 25 (67.6%) §0.004* 
Pacemaker 3 (3.7%) 1 (3.2%) 1 (2.7%) §1 
Echocardiography     
Mitral Regurgitation (x/4) 3.1 (0.6) 3.2 (0.7) 3.1 (0.6) 0.622 
Tricuspid Regurgitation 
(x/4) 
1.06 (0.47) 2.3 (0.4) 2.6 (0.8) 0.018* 
RV-RA gradient (mmHg) 29 (9) 43 (13) 37 (14) 0.179 
LVEDD (mm) 52 (10) 51 (12) 51 (9.6) 0.996 
LVEF (%) 60 (13) 62 (12) 59 (12) 0.385 
RV diameter (mm) 29 (5) 31 (7) 33 (6) 0.412 
TV annular diameter (mm) 30 (5) 32 (7) 34 (6) 0.412 
TV annular diameter≥40 mm 
or>21 mm/m2  
3 (4.8%) 9 (29%) 12 (32%) 0.798 
TAPSE (mm) 22 (5) 23 (4) 18 (4) <0.0001* 
Indication for surgery     
Degenerative 57 (70%) 22 (71%) 26 (70%) §0.639 
Flail leaflet 5 (6%) 2 (7%) 4 (11%)  
Prolaps 30 (37%) 7 (23%) 4 (11%)  
Degenerative/calcified 22 (27%) 13 (42%) 18 (48%)  
Functional 14 (17%) 5 (16%) 4 (11%)  
Ischemic 7 (8.5%) 5 (16%) 4 (11%)  
Cardiomyopathy other 7 (8.5%) 0 (0%) 0 (0%)  
Rheumatic 11 (13%) 4 (13%) 7 (19%)  
+ CABG 24 (29%) 11 (35%) 9 (25%) §0.424 
Post-operative      
30-day all-cause mortality 2 (2.4%) 3 (9.7%) 0 (0%) §0.090 
3-month all-cause mortality 3 (3.7%) 4 (12.9%) 2 (5.4%) §0.400 
Duration ITE stay (days) 5 (8) 6 (12) 6 (9) 0.829 
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Duration 
hospitalization(days) 
18 (18) 19 (17) 26 (39) 0.399 
New onset atrial fibrillation 18 (34.6%) 4 (30.8%) 4 (33.3%) §1 
New permanent pacemaker 12 (15.2%) 3 (10%) 10 (27.8%) §0.153 
 
Data of Group TR+/MVS were compared to Group TR+/MVS+TA using the unpaired t-test 
or §Fishers’ exact test where applicable. Continuous data and categorical data are represented 
by means and standard deviation or frequencies and percentages, respectively.  
TR-=tricuspid regurgitation<2/4; TR+=tricuspid regurgitation≥2/4; MVS=mitral valve 
surgery; TA=tricuspid annuloplasty; BMI= body mass index; RV=right ventricle; 
LVEDD=left ventricular end-diastolic diameter; LVEF=left ventricular ejection fraction; 
TAPSE=tricuspid annular plane systolic excursion; CABG=Coronary Artery Bypass 
Grafting.  
*p<0.05=significant. 
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Table 2: Comparison of mitral regurgitation severity, tricuspid regurgitation severity 
and New York Heart Association (NYHA) functional class within each surgical group.  
  Group 1 Group 2 Group 3 Group  
2 vs 3   TR-/MVS TR+/MVS TR+/MVS+TA 
 N Mean (SD) Paired 
t-test 
N Mean (SD) Paired  
t-test 
N Mean (SD) Paired  
t-test 
Unpaired 
t-test 
MR           
Preop 82 3.11 (0.63)  31 3.21 (0.67)  37 3.14 (0.57)  0.622 
Postop 80 0.44 (0.71) <0.0001* 29 0.48 (0.74) <0.0001* 36 0.68 (0.81) <0.0001* 0.308 
6months 78 0.71 (0.87) <0.0001* 24 0.71 (0.91) <0.0001* 34 0.88 (0.78) <0.0001* 0.437 
3 years 72 0.86 (0.66) <0.0001* 22 1.16 (0.70) <0.0001* 28 1.23 (0.69) <0.0001* 0.712 
5 years 58 0.87 (0.65) <0.0001* 16 1.47 (0.72) <0.0001* 21 1.43 (0.68) <0.0001* 0.863 
TR           
Preop 82 1.06 (0.47)  31 2.27 (0.44)  37 2.65 (0.80)  0.023* 
Postop 80 1.44 (0.84) <0.0001* 29 1.78 (0.86) 0.019* 36 1.15 (0.74) <0.0001* 0.003* 
6months 78 1.30 (0.85) 0.009* 24 1.90 (0.92) 0.110 34 1.46 (0.91) <0.0001* 0.076 
3 years 72 1.51 (0.67) <0.0001* 22 1.98 (0.88) 0.178 28 1.68 (0.74) <0.0001* 0.197 
5 years 58 1.63 (0.75) <0.0001* 16 2.19 (0.77) 0.523 21 1.74 (0.68) 0.010* 0.069 
NYHA           
Preop 82 2.2 (0.9)  31 2.5 (0.8)  37 2.6 (0.7)  0.741 
6months 78 1.5 (0.7) <0.0001* 26 1.7 (0.9) <0.0001* 35 1.6 (0.7) <0.0001* 0.753 
 
Preoperative values were compared with values immediately post-operative and at 6 months, 
3 years and 5 years. Mitral regurgitation was reduced in all study groups.  
TR+ indicates TR≥2/4 preoperatively. MVS indicates isolated mitral valve surgery. 
MVS+TA indicates additional tricuspid annuloplasty. TR-=tricuspid regurgitation<2/4; 
TR+=tricuspid regurgitation≥2/4; MVS=mitral valve surgery; TA=tricuspid annuloplasty.  
*p<0.05=significant. 
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Table 3: Medium-term event-rate for each group studied.  
 
 
 
 
 
 
 
 
 
The combined endpoint was composed of cardiac death and hospitalization for heart failure.  
TR-=tricuspid regurgitation<2/4; TR+=tricuspid regurgitation≥2/4; MVS=mitral valve 
surgery; TA=tricuspid annuloplasty. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TR-/MVS TR+/MV
S 
TR+/MVS+
TA 
Combined endpoint 
30 days 3 (4%) 3 (10%) 0 (0%) 
1 year 10 (12%) 9 (29%) 2 (6%) 
5 years 17 (22%) 16 (57%) 13 (39%) 
Cardiac-related death 
30 days 2 (2%) 3 (10%) 0 (0%) 
1 year 3 (4%) 5 (16%) 2 (6%) 
5 years 5 (7%) 7 (25%) 7 (20%) 
Hospitalization for heart failure  
30 days 1 (1%) 0 (0%) 0 (0%) 
1 year 7 (9%) 4 (13%) 0 (0%) 
5 years 12 (15%) 9 (33%) 6 (19%) 
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FIGURES: 
Figure 1: Flow chart to identify patients eligible for analysis 
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Figure 2: Unadjusted event-free survival for (A) Cardiac mortality and (B) Cardiac 
mortality or hospitalization for heart failure.  
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Figure 3: Propensity matched adjusted event-free survival for (A) cardiac mortality and 
(B) Cardiac mortality or hospitalization for heart failure in patients with significant 
preoperative functional tricuspid regurgitation (TR ≥2/4).  
 
 
 
 
 
 
